Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Antimicrobial Resistance or Delayed Appropriate Therapy-Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?

Lodise TP, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Bonine NG.

Open Forum Infect Dis. 2019 Apr 23;6(6):ofz194. doi: 10.1093/ofid/ofz194. eCollection 2019 Jun.

2.

The Emperor's New Clothes: Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE).

Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler V, Holland TL; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2019 Jun 3. pii: ciz460. doi: 10.1093/cid/ciz460. [Epub ahead of print]

PMID:
31157370
3.

Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model.

Avedissian SN, Pais GM, O'Donnell JN, Lodise TP, Liu J, Prozialeck WC, Joshi MD, Lamar PC, Becher L, Gulati A, Hope W, Scheetz MH.

J Antimicrob Chemother. 2019 May 7. pii: dkz167. doi: 10.1093/jac/dkz167. [Epub ahead of print]

PMID:
31065686
4.

Comparative performance of urinary biomarkers for vancomycin induced kidney injury according to timeline of injury.

Pais GM, Avedissian SN, O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Lamar PC, Cluff C, Gulati A, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH.

Antimicrob Agents Chemother. 2019 Apr 15. pii: AAC.00079-19. doi: 10.1128/AAC.00079-19. [Epub ahead of print]

PMID:
30988153
5.

Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents.

Rizk ML, Bhavnani SM, Drusano G, Dane A, Eakin AE, Guina T, Jang SH, Tomayko JF, Wang J, Zhuang L, Lodise TP.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02309-18. doi: 10.1128/AAC.02309-18. Print 2019 May. Review.

6.

Myelosuppression with Oxazolidinones: Are There Differences?

Hardalo C, Lodise TP, De Anda C.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01833-18. doi: 10.1128/AAC.01833-18. Print 2019 Jan. No abstract available.

7.
8.

Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.

Bland CM, Pai MP, Lodise TP.

Pharmacotherapy. 2018 Dec;38(12):1229-1238. doi: 10.1002/phar.2193.

PMID:
30403305
10.

Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?

Crass RL, Pai MP, Lodise TP Jr.

J Antimicrob Chemother. 2019 Jan 1;74(1):126-129. doi: 10.1093/jac/dky388.

PMID:
30252050
11.

The Importance of Individualized Vancomycin Dosing to Ensure Optimal Exposure Early in Therapy.

Zasowski EJ, Lodise TP.

J Clin Pharmacol. 2018 Sep;58(9):1131-1133. doi: 10.1002/jcph.1281. Epub 2018 Jul 19. No abstract available.

PMID:
30024648
12.

A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults.

Butterfield-Cowper JM, Lodise TP Jr, Pai MP.

Pharmacotherapy. 2018 Sep;38(9):981-985. doi: 10.1002/phar.2157. Epub 2018 Jul 12.

PMID:
29906315
13.

Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections.

Hardalo C, Lodise TP, Bidell M, Flanagan S, De Anda C, Anuskiewicz S, Prokocimer P.

Expert Opin Drug Saf. 2018 Apr;17(4):359-367. doi: 10.1080/14740338.2018.1446939. Epub 2018 Mar 12. Review.

PMID:
29528251
14.

Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.

McKinnell JA, Corman S, Patel D, Leung GH, Gordon LM, Lodise TP.

Clin Ther. 2018 Mar;40(3):406-414.e2. doi: 10.1016/j.clinthera.2018.01.010. Epub 2018 Feb 15.

15.

Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.

Lodise TP, Bosso J, Kelly C, Williams PJ, Lane JR, Huang DB.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01184-17. doi: 10.1128/AAC.01184-17. Print 2018 Feb.

16.

Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.

Natesan S, Pai MP, Lodise TP.

J Antimicrob Chemother. 2017 Oct 1;72(10):2813-2816. doi: 10.1093/jac/dkx221.

PMID:
29091209
17.

Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis.

Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL.

Crit Care Med. 2018 Jan;46(1):12-20. doi: 10.1097/CCM.0000000000002769. Review.

PMID:
29088001
18.

A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure.

Lodise TP, Fan W, Griffith DC, Dudley MN, Sulham KA.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01165-17. doi: 10.1128/AAC.01165-17. Print 2018 Jan.

19.

24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury.

O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Miglis CM, Joshi MD, Venkatesan N, Pais G, Cluff C, Lamar PC, Briyal S, Day JZ, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00416-17. doi: 10.1128/AAC.00416-17. Print 2017 Nov.

20.

Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies.

O'Donnell JN, Rhodes NJ, Miglis CM, Catovic L, Liu J, Cluff C, Pais G, Avedissian S, Joshi MD, Griffin B, Prozialeck W, Gulati A, Lodise TP, Scheetz MH.

Int J Antimicrob Agents. 2018 Feb;51(2):239-243. doi: 10.1016/j.ijantimicag.2017.08.012. Epub 2017 Aug 10. Review.

21.

Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.

Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Faragon C, Malik M, Mendes RE, Jones RN, McNutt LA, Lodise TP.

BMC Infect Dis. 2017 Aug 2;17(1):534. doi: 10.1186/s12879-017-2609-0.

22.

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.

Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR.

Open Forum Infect Dis. 2017 Jan 19;4(1):ofw274. doi: 10.1093/ofid/ofw274. eCollection 2017 Winter.

23.

Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.

Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Lodise TP.

Diagn Microbiol Infect Dis. 2017 Jul;88(3):259-263. doi: 10.1016/j.diagmicrobio.2017.03.008. Epub 2017 Apr 2.

24.

Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Doernberg SB, Lodise TP, Thaden JT, Munita JM, Cosgrove SE, Arias CA, Boucher HW, Corey GR, Lowy FD, Murray B, Miller LG, Holland TL; Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG).

Clin Infect Dis. 2017 Mar 15;64(suppl_1):S24-S29. doi: 10.1093/cid/ciw828. Review.

25.

Correction for Rhodes et al., Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00185-17. doi: 10.1128/AAC.00185-17. Print 2017 Apr. No abstract available.

26.

Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling.

Carreno JJ, Lomaestro B, Tietjan J, Lodise TP.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02478-16. doi: 10.1128/AAC.02478-16. Print 2017 May.

27.
28.

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.

Rahbar AJ, Lodise TP, Abraham P, Lockwood A, Pai MP, Patka J, Rabinovich M, Curzio K, Chester K, Williams B, Morse B, Chaar M, Huang V, Salomone J.

Surg Infect (Larchmt). 2016 Dec;17(6):675-682. Epub 2016 Nov 14.

PMID:
27841954
29.

Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5742-51. doi: 10.1128/AAC.00591-16. Print 2016 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Mar 24;61(4):.

30.

Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.

Lodise TP, Bidell MR, Flanagan SD, Zasowski EJ, Minassian SL, Prokocimer P.

J Antimicrob Chemother. 2016 Sep;71(9):2553-8. doi: 10.1093/jac/dkw206. Epub 2016 Jun 17.

PMID:
27317442
31.

Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.

Jensen IS, Wu E, Fan W, Lodise TP, Nicolau DP, Dufour S, Cyr PL, Sulham KA.

J Manag Care Spec Pharm. 2016 Jun;22(6):752-64. doi: 10.18553/jmcp.2016.22.6.752.

32.

Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?

Bidell MR, Lodise TP.

Pharmacotherapy. 2016 Jun;36(6):679-93. doi: 10.1002/phar.1761. Epub 2016 Jun 11. Review.

PMID:
27138564
33.

Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae.

Martirosov DM, Lodise TP.

Diagn Microbiol Infect Dis. 2016 Jun;85(2):266-75. doi: 10.1016/j.diagmicrobio.2015.10.008. Epub 2015 Oct 14. Review.

PMID:
27033631
34.
35.
36.

Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, Sulham KA.

Clin Drug Investig. 2016 Feb;36(2):157-68. doi: 10.1007/s40261-015-0365-8.

37.
38.

Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia.

Culshaw D, Lamp KC, Yoon MJ, Lodise TP.

Diagn Microbiol Infect Dis. 2015 Oct;83(2):193-7. doi: 10.1016/j.diagmicrobio.2015.06.003. Epub 2015 Jun 11.

39.

Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.

Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ.

Antimicrob Agents Chemother. 2015;59(6):2978-85. doi: 10.1128/AAC.03970-14. Epub 2015 Mar 9.

40.

Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.

Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM.

Antimicrob Agents Chemother. 2015 Feb;59(2):1119-26. doi: 10.1128/AAC.03643-14. Epub 2014 Dec 8.

41.

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.

Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, Prokocimer P.

Antimicrob Agents Chemother. 2015 Feb;59(2):864-71. doi: 10.1128/AAC.03688-14. Epub 2014 Nov 24.

42.

Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients.

Zasowski E, Bland CM, Tam VH, Lodise TP.

J Antimicrob Chemother. 2015 Mar;70(3):877-81. doi: 10.1093/jac/dku435. Epub 2014 Nov 6.

PMID:
25381169
43.

Efficacy and Hospitalization Length of Stay of Single Dose Oritavancin Compared to 7-10 Days of Vancomycin in Patients with Acute Bacterial Skin and Skin Structure Infections in the Us and Eastern Europe.

LaPensee K, Fan W, Fiset C, Jiang H, Lodise TP.

Value Health. 2014 Nov;17(7):A664. doi: 10.1016/j.jval.2014.08.2445. Epub 2014 Oct 26. No abstract available.

44.

Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit?

Rahme C, Butterfield JM, Nicasio AM, Lodise TP.

Diagn Microbiol Infect Dis. 2014 Dec;80(4):239-59. doi: 10.1016/j.diagmicrobio.2014.07.007. Epub 2014 Jul 31. Review.

PMID:
25308565
45.

Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.

Lodise TP, Fang E, Minassian SL, Prokocimer PG.

Antimicrob Agents Chemother. 2014 Dec;58(12):7198-204. doi: 10.1128/AAC.03509-14. Epub 2014 Sep 22.

46.

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE.

Carreno JJ, Lodise TP.

Infect Dis Ther. 2014 Dec;3(2):123-32. doi: 10.1007/s40121-014-0036-8. Epub 2014 Sep 6. Review.

47.

Innovative approaches to optimizing the delivery of vancomycin in individual patients.

Pai MP, Neely M, Rodvold KA, Lodise TP.

Adv Drug Deliv Rev. 2014 Nov 20;77:50-7. doi: 10.1016/j.addr.2014.05.016. Epub 2014 Jun 5. Review.

48.

Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?

Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA.

Clin Infect Dis. 2014 Sep 1;59(5):666-75. doi: 10.1093/cid/ciu398. Epub 2014 May 27.

PMID:
24867791
49.

Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .

Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L, McNutt LA.

J Antimicrob Chemother. 2014 Sep;69(9):2547-55. doi: 10.1093/jac/dku135. Epub 2014 May 19.

PMID:
24840624
50.

Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.

Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely MN, Hope WW.

Antimicrob Agents Chemother. 2014 Jul;58(7):4094-102. doi: 10.1128/AAC.02664-14. Epub 2014 May 5.

Supplemental Content

Loading ...
Support Center